File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma

TitleA phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma
Authors
KeywordsChemotherapy
Cisplatin
Metastasis
Nasopharyngeal carcinoma
Neoplasm recurrence
Pemetrexed
Issue Date2012
Citation
Oral Oncology, 2012, v. 48, n. 5, p. 441-444 How to Cite?
AbstractPemetrexed is a novel chemotherapy agent with good efficacy and toxicity profiles. This phase II study aimed at evaluating its use in combination with cisplatin for recurrent or metastatic nasopharyngeal carcinoma (NPC). All participating patients had metastatic or recurrent NPC with prior treatment by platinum-based chemotherapy. The study regimen comprised of pemetrexed 500 mg/m 2 and cisplatin 75 mg/m 2, repeated 3-weekly for 4 cycles. Efficacy evaluation was based on both radiological and biochemical responses. Patients with no progressive disease and good tolerance were given another 2-4 cycles. Fifteen patients were treated for a total of 4-8 cycles (median, 6 cycles); 9 had distant metastases and 6 had loco-regional recurrences only. Reduction of DNA copies of EB virus by ≥50% was observed in 93% accessible patients, with 21% of them being biochemical complete response (CR). Radiologically, 1 (7%) patient achieved CR, 2 (13%) achieved partial response and 8 (53%) had stable diseases. The median time to progression was 30 weeks. Treatment was well tolerated with only 1 (7%) patient developing grade 4 toxicity (of anemia). The most common grade 3 toxicities were neutropenia (27%) and anemia (20%). The baseline mean total QOL scores (as measured with FACT-H&N version 4) was 100.4 and showed no significant change after the fourth cycle (95.6, p = 0.20) and sixth cycle (91.9, p = 0.15). Pemetrexed in combination with cisplatin is a well tolerated regimen with encouraging efficacy for metastatic and recurrent NPC. Further evaluation of its role in the management of NPC is warranted. © 2011 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/213963
ISSN
2015 Impact Factor: 4.286
2015 SCImago Journal Rankings: 1.764

 

DC FieldValueLanguage
dc.contributor.authorYau, T. K.-
dc.contributor.authorShum, T.-
dc.contributor.authorLee, A. W M-
dc.contributor.authorYeung, M. W.-
dc.contributor.authorNg, W. T.-
dc.contributor.authorChan, L.-
dc.date.accessioned2015-08-19T13:41:23Z-
dc.date.available2015-08-19T13:41:23Z-
dc.date.issued2012-
dc.identifier.citationOral Oncology, 2012, v. 48, n. 5, p. 441-444-
dc.identifier.issn1368-8375-
dc.identifier.urihttp://hdl.handle.net/10722/213963-
dc.description.abstractPemetrexed is a novel chemotherapy agent with good efficacy and toxicity profiles. This phase II study aimed at evaluating its use in combination with cisplatin for recurrent or metastatic nasopharyngeal carcinoma (NPC). All participating patients had metastatic or recurrent NPC with prior treatment by platinum-based chemotherapy. The study regimen comprised of pemetrexed 500 mg/m 2 and cisplatin 75 mg/m 2, repeated 3-weekly for 4 cycles. Efficacy evaluation was based on both radiological and biochemical responses. Patients with no progressive disease and good tolerance were given another 2-4 cycles. Fifteen patients were treated for a total of 4-8 cycles (median, 6 cycles); 9 had distant metastases and 6 had loco-regional recurrences only. Reduction of DNA copies of EB virus by ≥50% was observed in 93% accessible patients, with 21% of them being biochemical complete response (CR). Radiologically, 1 (7%) patient achieved CR, 2 (13%) achieved partial response and 8 (53%) had stable diseases. The median time to progression was 30 weeks. Treatment was well tolerated with only 1 (7%) patient developing grade 4 toxicity (of anemia). The most common grade 3 toxicities were neutropenia (27%) and anemia (20%). The baseline mean total QOL scores (as measured with FACT-H&N version 4) was 100.4 and showed no significant change after the fourth cycle (95.6, p = 0.20) and sixth cycle (91.9, p = 0.15). Pemetrexed in combination with cisplatin is a well tolerated regimen with encouraging efficacy for metastatic and recurrent NPC. Further evaluation of its role in the management of NPC is warranted. © 2011 Elsevier Ltd. All rights reserved.-
dc.languageeng-
dc.relation.ispartofOral Oncology-
dc.subjectChemotherapy-
dc.subjectCisplatin-
dc.subjectMetastasis-
dc.subjectNasopharyngeal carcinoma-
dc.subjectNeoplasm recurrence-
dc.subjectPemetrexed-
dc.titleA phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.oraloncology.2011.12.001-
dc.identifier.pmid22206807-
dc.identifier.scopuseid_2-s2.0-84860013938-
dc.identifier.hkuros266361-
dc.identifier.volume48-
dc.identifier.issue5-
dc.identifier.spage441-
dc.identifier.epage444-
dc.identifier.eissn1879-0593-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats